Dr. Elyse Watkins, DHSc, PA-C
Purpose: The purpose of this article is to achieve a functional understanding of the EMPA-REG study, describe how these results should be implemented clinically, and to explore whether or not a SGLT2 class wide effect may be present and by what mechanism of action.
Results: Reduced risk of death by cardiovascular events, reduced hospitalization rates due to heart failure, reduced all cause mortality, in type 2 diabetics with known cardiovascular disease.
Conclusion: Based on best evidence available, in type 2 diabetic patients with known cardiovascular disease, empagliflozin shows reduction in cardiovascular death by thirty-eight percent, reduction in hospitalization for heart failure by thirty-five percent, and reduction in all cause total mortality by thirty-two percent. Therefore empagliflozin should be utilized in any patient fitting this demographic, and a type 2 diabetic patient with known cardiovascular disease currently taking a different SGLT2 inhibitor should be switched to empagliflozin. There is currently no exact mechanism of action known to be responsible for these cardiovascular benefits. Research to support the cardiovascular benefits as a SGLT2 inhibitor class wide effect is currently being completed.
"The Novel Role of Empagliflozin (Jardiance) in Type 2 Diabetes and Cardiovascular Disease,"
Lynchburg Journal of Medical Science: Vol. 1
, Article 56.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol1/iss4/56
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.